Advagene Biopharma Co., Ltd. (TPEX:6709)

Market Cap	1.40B -33.1%
Revenue (ttm)	n/a
Net Income	-91.05M
EPS	-1.52
Shares Out	59.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,716
Open	22.95
Previous Close	24.05
Day's Range	22.70 - 23.90
52-Week Range	22.50 - 36.15
Beta	0.68
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Advagene Biopharma

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 16
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6709

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error